
0:00
24:24
We sit down with Shawn Manchester, CEO of TripleBar, whose path from yeast DNA repair to metabolic engineering at MIT to biomanufacturing AI gave him a front-row seat to one of biotech's most underappreciated problems.
Everyone funds discovery. Nobody funds manufacturing. And yet a molecule that can't be made reliably and cheaply at scale never reaches a patient. Shawn makes the case that biomanufacturing is where the real bottleneck lives, and why it's finally getting the AI attention it deserves. It's a refreshingly grounded conversation about what biological AI actually requires to work.
More episodes from "From Models to Medicine"



Don't miss an episode of “From Models to Medicine” and subscribe to it in the GetPodcast app.








